1-1 of 1
Keywords: angiogenesis inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?

In Collection
Cardiovascular-Oncology
Daan C.H. van Dorst, Leni van Doorn, Katrina M. Mirabito Colafella, Olivier C. Manintveld, H. Carlijne Hassing, A.H. Jan Danser, Ron H.J. Mathijssen, Jorie Versmissen
Journal: Clinical Science
Clin Sci (Lond) (2021) 135 (14): 1649–1668.
DOI: https://doi.org/10.1042/CS20200300
Published: 20 July 2021
... Limited on behalf of the Biochemical Society 2021 angiogenesis inhibitors atherosclerosis cardio-oncology cardiovascular toxicity hypertension immune checkpoint inhibitors In the past two decades, the development of a multitude of targeted anti-cancer therapies has substantially...
View article titled, Cardiovascular toxicity of <span class="search-highlight">angiogenesis</span> <span class="search-highlight">inhibitors</span> and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?
Click here to open pdf in another window PDF for Cardiovascular toxicity of <span class="search-highlight">angiogenesis</span> <span class="search-highlight">inhibitors</span> and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?